eureKARE ssuccessfully hosts Iinaugural SynBio day and EureKAWARDS
- Congratulations to the first eurKAWARDS pitch competition winner, Pr. Roy Bar-Ziv of the Weizmann Institute of Science
- Tthank you all the to assistees and our partners Potter Clarkson, ERS Genomics and the District VCLS Innovation Center
- eureKARE looks forward to welcoming everyone again in 2022 for the next SynBio Day
Luxembourg and Paris, France – 19 November 2021: eureKARE (“the Company”), a pioneering new company focused on funding and building next-generation biotechnology companies in the disruptive fields of synthetic biology and the microbiome, has successfully concluded its first eureKARE SynBio Day November 10e, 2021. The event brought together over 200 industry, academia and investment stakeholders interested in synthetic biology. The day was filled with impactful sessions led by esteemed speakers who provided industry insight to highlight the importance of synthetic biology. An expert roundtable also explored challenges, ranging from societal views and policies to funding and regulation.
eureKARE would like to thank all the participants of the first SynBio Day and our partners, Potter Clarkson, ERS Genomics and Neighborhood VCLS ‘Innovation Center, for contributing to the success of the event.
Eurekare SynBio Day also marked the culmination of eurekaward’s first pitch competition, which sought out innovative synthetic biology start-up ideas from Europe, the UK and Israel. eureKARE thanks the team of experts from leading companies and research institutes across Europe who composed the jury that reviewed and selected the finalists for the eureKAWARDS.
EureKAWARDS has received a number of innovative and high-quality submissions from several countries and eureKARE would like to congratulate Professor Roy Bar-Ziv of the Weizmann Institute of Science in Israel as the winner of the very first eureKAWARDS. Roy Bar-Ziv’s submission, combining physics with biology and artificial microarray cell technology, stood out from the jury for its scientific excellence and highly disruptive approach to diagnosis and therapy. As a winner, Roy will be able to benefit from free access to premium services provided by the team of the start-up studio eureKASYNBIO and its network of validated partners for one year. He will also benefit from the advice and support of the eurekare team and a vast network of university and industrial professionals validated in synthetic biology.
Rodolphe Besserv, eureKARE CEO, commented: “i am delighted through the success of our very first SynBio Day who outmoded our expectations. I would like to personally congratulate Roy on winning the eurKAWARDS and thank all those who participated, specifically our speakers, jury, aand my colleagues who worked hard to achieve such a smooth and successful event. We are happy to get played a role in highlighting the importance of synthetic biology space, a critic field of research in today’s era. We hope to continue contribute to the field and I’m already looking cheeky To SynBio Day 2022.“
Special thanks from eurekare to:
- Jean-David Malo, Director of the Executive Agency for EICs and SMEs (EISMEA)
- Dr AndrÃ© Choulika, CEO and director of Cellectis
- Prof. Antoine Danchin, CSOs of Kodikos Labs and president of eureKARE SAB
- Dr David Bikard, CTO and co-founder of Eligo Biosciences
- Dr Iordanis Arzimanoglou, EIC Program Manager, Health and Biotechnology
- Dr Pamela Silver, professor of systems biology at Harvard Medical School and member of eureKARE SAB
- Teacher. Dr Petra Schwille, Director, Cellular and Molecular Biophysics Max Planck Institute of Biochemistry
- Dr Siyuan Chen, CTO of Twist Bioscience
Our moderator and panelists of the round table:
Nastassia Astrasheuskaya, Financial Time, Dr Karen Fallen, CEO, Touchlight, Anya Roy, Head of Illumina Accelerator UK, Ana Atanassova, Global Regulatory Policy, BASF AP, Teacher. Darian Meacham, Maastricht University, Dr Rodrigo Ledesma Amaro, Team Leader, Imperial College London, Fiona Mischel, Director of International Outreach, Synbiobeta, Dr Yuval Dorfan, IDC, Israeli SynBio founding director of the institute.
The eureKAWARDS Jury was made up of:
Siau Bai, Director of Early Innovation Partnerships for Johnson and Johnson Innovation, Marc Chevalier, Boss of Bio-entrepreneurship at the Imagine Institute of Genetic Diseases, SÃ©bastien Giraudier, District Director, VCLS Innovation Center, Neil Goldsmith, Co-founder of Evolva and Serial Entrepreneur in Synthetic Biology, AurÃ©lie Grienenberger, CBO at Eligo Bioscience, Sara Holland, Senior Associate UK and European Patent Attorney at Potter Clarkson, Richard Reschen, Associate Director Business Development & Licensing at MSD, Eric Rhodes, CEO of ERS Genomics.
The eurekare Scientific Council acting as Scientific Jury comprising:
Pr Antoine Danchin, Dr JoÃ«l DorÃ©, Dr Leroy Hood, Dr Philippe MarliÃ¨re, Pr Dr Sven Panke, Dr Felix Rey, Dr Pamela Silver and Dr George Weinstock.
– To finish –
eureKARE is a unique project development company dedicated to investing and developing next-generation biotechnology companies in the cutting edge fields of microbiome and synthetic biology. eureKARE has a two-step investment approach to creating long-term value. The Company supports translational research by creating and financing new companies resulting from European science with high added value through its biotechnology start-ups eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology). The Company also intends to invest in more mature biotechnology companies and will systematically offer to offer liquidity to early investors, thus meeting a critical need in the field of European biotechnologies. Guided by its influential founder, Alexandre Mouradian, and a pan-European team, eureKARE has a portfolio of rapidly growing companies that have the potential to disrupt the life sciences industry.
For more information
Marina Shapochnik, Head of Investor Relations
Strategic Communication Consilium
Ambre Fennell, Sukaina Virji, GeneviÃ¨ve Wilson
+44 (0) 203 709 5000